{"title":"Weight Loss","description":"\u003ch1\u003ePeptides with metabolic effects\u003c\/h1\u003e\n\u003cp\u003ehave been studied for their effects related to lipolysis, appetite control, energy balance, and regulation of metabolic pathways. Among them, Retatrutide shows the strongest weight loss results in scientific research.\u003c\/p\u003e","products":[{"product_id":"acjc-1295","title":"CJC-1295 (no DAC) 5mg","description":"\u003ch1\u003eWhat is CJC-1295?\u003c\/h1\u003e\n\u003cp class=\"p1\"\u003eCJC-1295 (Mod GRF 1-29) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH), composed of 29 amino acids. The modified form, known as Mod GRF 1-29, contains specific amino acid substitutions that enhance its stability and biological activity compared to the original Sermorelin. Published scientific literature describes that CJC-1295 supports the physiological release of growth hormone (GH) by stimulating the pituitary gland, intensifying natural secretion pulses. It is often considered in combination with GHRP peptides, such as Ipamorelin, due to a potential synergistic effect on GH release.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e \u003c\/p\u003e\n\n\u003ch2\u003eObservations with CJC-1295\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eCJC-1295 (Mod GRF 1-29) is studied in relation to the following physiological processes:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eGrowth Hormone Stimulation – activation of GH pulses and an increase in IGF-1 have been observed in scientific models.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eInfluence on anabolic processes and protein synthesis.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eSupport for joint and bone health – effects on mineralization and recovery of tendons and bones have been described.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eRegeneration and recovery – an observed role in recovery processes after physical exertion.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eSleep quality – associated with supporting deep sleep phases.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eEffects on tissue regeneration – considered in relation to recovery and cell renewal processes.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eMetabolic action – a connection with lipolysis and fat metabolism has been observed in research models.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp\u003eIn scientific literature, subcutaneous administration once daily in the range of 100–300 μg, usually in the evening before sleep, is most commonly described.\u003c\/p\u003e\n\u003cp\u003eFor 5 mg + 3 ml bacteriostatic water:\u003c\/p\u003e\n\u003cp\u003eConcentration = 1.67 mg\/ml → 0.06 ml = 100 μg\u003c\/p\u003e\n\u003cp\u003eApproximate values for 5 mg:\u003c\/p\u003e\n\u003cp\u003e0.06 ml = 100 μg\u003c\/p\u003e\n\u003cp\u003e0.12 ml = 200 μg\u003c\/p\u003e\n\u003cp\u003e0.18 ml = 300 μg\u003c\/p\u003e\n\u003cp\u003e0.24 ml = 400 μg\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2 class=\"p1\"\u003eScientific Data\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eCJC-1295 has been the subject of clinical and preclinical studies in various fields.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn endocrinology, it is considered due to its ability to increase GH and IGF-1 levels with good tolerability.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn sports medicine, interest is related to recovery, maintenance of muscle mass, and reduction of adipose tissue.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn gerontology, it is studied for its potential role in maintaining higher levels of GH and IGF-1 with advancing age.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eCombining with GHRP peptides is often considered a more effective approach compared to standalone administration.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e \u003c\/p\u003e\n\n\u003ch2 class=\"p1\"\u003eApplication in Sports\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eCJC-1295 is included in WADA's prohibited list for professional sports as it can:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003estimulate growth hormone release\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eaid in muscle and tendon recovery\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003epositively affect muscle mass and strength\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eparticipate in fat reduction processes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\n\u003ch2 class=\"p1\"\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eReported adverse reactions in scientific literature are usually rare and mild in nature:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eredness or discomfort at the injection site\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003efatigue\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eheadache\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003emild fluid retention\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003eLess commonly, dizziness or temporary changes in appetite may be observed.\u003c\/p\u003e\n\n\u003cp class=\"p1\"\u003e\u003cem\u003e\u003cspan class=\"s1\"\u003eThe information is gathered and systematized from various scientific publications and studies. It serves \u003c\/span\u003esolely for educational purposes\u003cspan class=\"s1\"\u003e and \u003c\/span\u003eshould not be used for the diagnosis, treatment, or prevention of diseases\u003cspan class=\"s1\"\u003e.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"5mg","offer_id":53386104766807,"sku":"PP-CJC1295-NODAC-5MG","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/cjc-1295-no-dacbr5mg-2052321_1247463f-acf2-41a5-80a6-f6dff48584af.png?v=1779544802"},{"product_id":"axchgh-frag-176-191","title":"hGH frag (176-191) 5mg","description":"\u003ch1\u003eWhat is hGH Frag 176-191?\u003c\/h1\u003e\n\u003cp class=\"p1\"\u003ehGH Fragment 176-191 is a synthetic peptide fragment constructed from the amino acid sequence 176-191 of the C-terminal portion of human growth hormone (hGH). This molecule was developed to separately investigate the lipolytic properties attributed to certain segments of GH, without reproducing the full physiological profile of growth hormone. In scientific literature, hGH Frag 176-191 has been considered a model compound for studies on lipolysis, lipid metabolism, and energy balance.\u003c\/p\u003e\n\n\u003c!-- Изображение --\u003e\n\n\u003cp class=\"p1\"\u003eUnlike full-length hGH, hGH Frag 176-191 is not associated with a significant increase in IGF-1 and does not demonstrate the typical growth effects on tissues and organs. Instead, in experimental models, the peptide has been associated with stimulating fatty acid breakdown and limiting lipogenesis processes. Therefore, it is used as a research tool in studying mechanisms related to fat metabolism and metabolic regulation.\u003c\/p\u003e\n\n\u003cp class=\"p1\"\u003e \u003c\/p\u003e\n\n\u003ch2\u003eObservations on HGH Frag 176-191\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eIn published scientific literature, HGH Frag 176-191 has been investigated in relation to the following:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eStimulation of lipolysis – aids in the breakdown of fatty acids in adipocyte models\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eInhibition of lipogenesis – associated with limiting the accumulation of new fat deposits\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eRegulation of body weight – considered a potential model for metabolic modulation\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eMaintenance of lean muscle mass – without the pronounced anabolic profile characteristic of full GH\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eReduction of visceral adipose tissue – observed in models related to obesity\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eInsulin sensitivity – effects described in some preclinical studies\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp\u003eIn scientific publications and experimental protocols, amounts in the range of 250-500 μg daily are found, typically administered subcutaneously under controlled research conditions and often divided into 1-2 applications. The peptide is most often considered in short-term research models focused on lipolytic mechanisms. hGH Frag 176-191 is among the more hydrophobic peptides, which may limit its solubility and typically requires using the entire solution.\u003c\/p\u003e\n\n\u003cp\u003eFor 5 mg + 3 ml bacteriostatic water:\u003c\/p\u003e\n\u003cp\u003eConcentration = 1.67 mg\/ml → 0.06 ml = 100 μg\u003c\/p\u003e\n\u003cp\u003eExample values:\u003c\/p\u003e\n\u003cp\u003e0.06 ml = 100 μg\u003c\/p\u003e\n\u003cp\u003e0.12 ml = 200 μg\u003c\/p\u003e\n\u003cp\u003e0.18 ml = 300 μg\u003c\/p\u003e\n\u003cp\u003e0.24 ml = 400 μg\u003c\/p\u003e\n\n\u003ch2\u003e\u003c\/h2\u003e\n\n\u003ch2\u003eScientific Data\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eHGH Frag 176-191 has been primarily the subject of preclinical studies, as well as limited clinical observations. The main scientific data described include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eIncreased lipolytic activity in adipocyte cultures and experimental models\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eReduction of total and visceral adipose tissue without significant changes in IGF-1 levels\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eLack of a distinct effect on glucose homeostasis at low experimental quantities\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eAbsence of observed influence on organ and tissue growth\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eImprovements in lipid metabolism and energy efficiency in some preclinical models\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003eApplication in Sports and Research Settings\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eHGH Fragment 176-191 is listed by WADA as a controlled substance and is not permitted for use by professional athletes. In laboratory and academic contexts, the peptide is used to study lipolytic processes, energy metabolism, and models related to metabolic syndrome, obesity, and insulin resistance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eModel for studying mechanisms related to fat tissue reduction\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eStudies on insulin sensitivity, lipid metabolism, and energy balance\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eInvestigation of potential interaction with other peptides involved in metabolic regulation\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eIn the available scientific literature, HGH Frag 176-191 is generally described as well-tolerated within research settings. Observed reactions are primarily mild and transient:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eLocal redness or discomfort at the experimental application site\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eMild fatigue or drowsiness\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp class=\"p1\"\u003eHeadache at higher experimental quantities\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp class=\"p1\"\u003eNo serious adverse reactions at research quantities are reported in the published data. The described effects are primarily dose-dependent, temporary, and dependent on the conditions of the specific model.\u003c\/p\u003e\n\n\u003cp class=\"p1\"\u003e\u003cem\u003eThe information is based on scientific literature and is for educational purposes. It does not constitute medical advice and is not intended for diagnosis, treatment, prevention, or use in humans or animals.\u003c\/em\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"5mg","offer_id":53386106339671,"sku":"PP-HGH-FRAG-5MG","price":35.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/hgh-frag-176-191br5mg-3748012_c7410536-5990-4c10-9435-3a63dfd65ce5.png?v=1779544815"},{"product_id":"sdc-tirzepatide","title":"Tirzepatide 5mg\/10mg","description":"\u003ch1 class=\"p1\"\u003eWhat is Tirzepatide?\u003c\/h1\u003e\n\u003cp class=\"p1\"\u003eTirzepatide is a synthetic peptide composed of 39 amino acids. The molecule belongs to the incretin analog group and exhibits dual activity on GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This combined receptor profile is precisely what distinguishes it from classic GLP-1 analogs, which primarily act on a single incretin pathway.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eInitially, Tirzepatide was developed in the context of type 2 diabetes mellitus, but clinical trials have also described a significant effect on body weight reduction. In research models, changes in insulin sensitivity, blood sugar control, body composition, and a number of metabolic and cardiovascular parameters have been observed.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e \u003c\/p\u003e\n\u003ch2\u003eObservations for Tirzepatide\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eTirzepatide is being investigated for its potential impact on several key metabolic areas:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eBlood sugar control – research and clinical models have observed a reduction in HbA1c and a limitation of glucose spikes.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eWeight reduction – an effect on reducing fat tissue and improving body composition has been described.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eMetabolic health – changes in lipid profile, hepatic steatosis, and other markers associated with metabolic risk have been observed.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eCardiovascular function – reductions in blood pressure and triglycerides have been described in research settings.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eEnergy homeostasis – an effect on appetite, energy balance, fat oxidation, and metabolic regulation has been observed.\u003c\/p\u003e\n\u003cp class=\"p3\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003eScientific Data\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eTirzepatide has been the subject of extensive clinical trials, in which it has emerged as an incretin analog with a pronounced effect on glycemic control and body weight.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn patients with type 2 diabetes mellitus, the following has been reported:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- HbA1c reduction by up to 2%\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- Weight loss of 10-15%\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- Improvement in lipid profile and blood pressure\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn people with obesity without diabetes, the following has been observed:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- Weight loss of up to 20% over 72 weeks\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- Reduction of visceral fat\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- Improvement in cardio-metabolic parameters\u003c\/p\u003e\n\u003cp class=\"p3\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eScientific literature describes once-weekly subcutaneous administration within clinical and research protocols.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eStandard doses: 2.5 mg - initial dose with gradual titration up to 5 mg weekly depending on tolerance and therapeutic effect.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eFor 5 mg + 2 ml bacteriostatic water:\u003c\/p\u003e\n\u003cp class=\"p2\"\u003eConcentration = 2.5 mg\/ml → 0.4 ml = 1 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003eExample values for 5 mg:\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.1 ml = 250μg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.2 ml = 500μg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.3 ml = 750μg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.4 ml = 1 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.5 ml = 1.25 mg\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eFor 10 mg + 2 ml bacteriostatic water:\u003c\/p\u003e\n\u003cp class=\"p2\"\u003eConcentration = 5 mg\/ml → 0.2 ml = 1 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003eExample values for 10 mg:\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.1 ml = 500μg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.2 ml = 1 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.3 ml = 1.5 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.4 ml = 2 mg\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e0.5 ml = 2.5 mg\u003c\/p\u003e\n\u003cp class=\"p3\"\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eThe most commonly reported reactions in clinical and research data are related to the gastrointestinal tract, especially during periods of dose escalation.\u003c\/p\u003e\n\u003cp class=\"p3\"\u003ePossible side effects are highly dose-dependent and include:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- nausea, vomiting, diarrhea, constipation\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- decreased appetite\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- abdominal discomfort\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eRarer but more serious risks include:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- pancreatitis\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- gallstone disease with rapid weight reduction\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e- hypoglycemia when combined with other antidiabetic agents\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cem\u003e\u003cspan class=\"s1\"\u003eThe information is collected and systematized from various scientific sources and studies. It is for educational purposes only and should not be used for diagnosis, treatment, or prevention of diseases.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"PurePeptide","offers":[{"title":"5mg","offer_id":53386107224407,"sku":null,"price":59.0,"currency_code":"EUR","in_stock":true},{"title":"10mg","offer_id":53386107257175,"sku":null,"price":99.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/Tirzepatide5mg_ff19f292-884d-4c41-be46-84615a825b0a.png?v=1779544821"},{"product_id":"afsretatrutide","title":"Retatrutide 5mg\/10mg\/30mg","description":"\u003ch1 class=\"p1\"\u003eWhat is Retatrutide?\u003c\/h1\u003e\n\u003cp\u003eRetatrutide is a peptide analog consisting of 42 amino acids, which is a subject of scientific interest mainly in the field of metabolic regulation. A distinctive feature of the molecule is its triple receptor profile – interaction with GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptors. This combined activity distinguishes it from classic GLP-1 analogs and places it among the more extensively studied incretin compounds.\u003c\/p\u003e\n\u003cp\u003eIn scientific literature, Retatrutide is primarily discussed in relation to obesity, type 2 diabetes, and other metabolic conditions. Published clinical data describe changes in body weight, glycemic control, and various cardiometabolic indicators in observed participant groups.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e \u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003eObservations and Data on Retatrutide\u003c\/h2\u003e\n\u003cp\u003eAvailable publications examine Retatrutide in several main areas related to metabolic function, energy balance, and appetite regulation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlucose control\u003c\/strong\u003e – clinical studies have described tendencies towards a reduction in HbA1c and an improvement in insulin sensitivity in some participants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeight reduction\u003c\/strong\u003e – published results show a significant reduction in body weight and fat mass, with effects being more pronounced in some protocols compared to compounds with a dual receptor mechanism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepatic metabolism\u003c\/strong\u003e – individual studies have reported changes in hepatic steatosis, as well as improvements in some lipid profile indicators.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardiometabolic markers\u003c\/strong\u003e – changes in triglycerides, systolic blood pressure, and certain inflammatory markers have been described.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnergy expenditure\u003c\/strong\u003e – experimental models suggest a possible influence on energy expenditure, utilization of fat stores, and mechanisms related to appetite.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch2\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp\u003eScientific publications most often describe subcutaneous administration once weekly. Various research protocols use gradual titration, with initial doses often starting at 2 mg weekly and subsequently increasing according to tolerability and observed results.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhen dissolving 5 mg with 2 ml bacteriostatic water:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe resulting concentration is 2.5 mg\/ml, meaning 0.4 ml contains 1 mg.\u003c\/p\u003e\n\u003cp\u003eApproximate values:\u003c\/p\u003e\n\u003cp\u003e0.1 ml = 0.25 mg\u003c\/p\u003e\n\u003cp\u003e0.2 ml = 0.5 mg\u003c\/p\u003e\n\u003cp\u003e0.3 ml = 0.75 mg\u003c\/p\u003e\n\u003cp\u003e0.4 ml = 1 mg\u003c\/p\u003e\n\u003cp\u003e0.5 ml = 1.25 mg\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhen dissolving 10 mg with 2 ml bacteriostatic water:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe resulting concentration is 5 mg\/ml, meaning 0.2 ml contains 1 mg.\u003c\/p\u003e\n\u003cp\u003eApproximate values:\u003c\/p\u003e\n\u003cp\u003e0.1 ml = 0.5 mg\u003c\/p\u003e\n\u003cp\u003e0.2 ml = 1 mg\u003c\/p\u003e\n\u003cp\u003e0.3 ml = 1.5 mg\u003c\/p\u003e\n\u003cp\u003e0.4 ml = 2 mg\u003c\/p\u003e\n\u003cp\u003e0.5 ml = 2.5 mg\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003eScientific Publications\u003c\/h2\u003e\n\u003cp\u003eRetatrutide has also been studied in the TRIUMPH-4 clinical trial, phase 3, conducted over 68 weeks in participants with obesity or overweight and concomitant knee osteoarthritis, without diagnosed diabetes.\u003c\/p\u003e\n\u003cp\u003eAccording to the published results, the following trends were observed during the study:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage body weight reduction of approximately 28.7% by week 68 in the 12 mg dose group.\u003c\/li\u003e\n\u003cli\u003eSignificant reduction in pain according to the WOMAC scale, combined with improvement in physical function and daily activity.\u003c\/li\u003e\n\u003cli\u003eFavorable changes in non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure at higher dose regimens.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch2 class=\"p1\"\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp class=\"p1\"\u003eThe most commonly described adverse reactions in scientific literature are related to the gastrointestinal system.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eThese are typically dose-dependent and may include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003enausea, vomiting, diarrhea, or constipation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003edecreased appetite\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003ebloating, feeling of heaviness, and abdominal discomfort\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003eLess frequently, publications also discuss potentially more serious risks, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003echolelithiasis, especially with rapid body weight reduction\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003ehypoglycemia when combined with antidiabetic therapies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003e\u003cem\u003e\u003cspan class=\"s1\"\u003eThe information is summarized based on available scientific publications and clinical observations. It is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"PurePeptide","offers":[{"title":"5mg","offer_id":53386107289943,"sku":null,"price":59.0,"currency_code":"EUR","in_stock":true},{"title":"10mg","offer_id":53386107322711,"sku":null,"price":99.0,"currency_code":"EUR","in_stock":true},{"title":"30mg","offer_id":53386107355479,"sku":null,"price":199.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/Reta_5mg.png?v=1779544825"},{"product_id":"a-a-semaglutide","title":"Semaglutide 5mg\/10mg","description":"\u003ch1\u003eWhat is Semaglutide?\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e is a synthetic peptide analog, composed of 31 amino acids, primarily studied as a selective GLP-1 receptor agonist. Semaglutide belongs to the group of incretin analogs and is the subject of numerous scientific publications related to metabolic regulation, blood sugar control, and changes in body weight.\u003c\/p\u003e\n\u003ch2\u003eSemaglutide — Mechanism and Scientific Observations\u003c\/h2\u003e\n\u003cp\u003eIn scientific literature, Semaglutide is discussed in connection with the activation of GLP-1 receptors, which are involved in the regulation of glucose metabolism, appetite, and gastric emptying. The molecule is modified to have an extended half-life, allowing for research with weekly protocols.\u003c\/p\u003e\n\u003cp\u003eIn clinical and experimental observations, Semaglutide has been associated with a reduction in HbA1c, body weight reduction, improvement in lipid profile, and changes in cardio-metabolic parameters. Effects on appetite, energy homeostasis, and visceral fat have also been described.\u003c\/p\u003e\n\u003ch2\u003eScientific Data on Semaglutide\u003c\/h2\u003e\n\u003cp\u003eIn patients with type 2 diabetes, published studies have observed reductions in HbA1c, weight reduction, and improvements in some metabolic markers. In people with obesity without diabetes, average changes in body weight of 12–15% over a period of up to 68 weeks have been described.\u003c\/p\u003e\n\u003cp\u003eSemaglutide continues to be the subject of active scientific research related to metabolic disorders, insulin sensitivity, and cardiovascular parameters. Changes in appetite, caloric intake, and body composition have been observed in various research models.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eThe most commonly reported reactions to Semaglutide are related to the gastrointestinal tract and include nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort. Rarer but more serious risks include pancreatitis, cholelithiasis, and hypoglycemia when combined with other antidiabetic agents.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThe information is compiled and systematized from scientific sources and serves educational purposes only. It should not be used for diagnosis, treatment, or prevention of diseases.\u003c\/em\u003e\u003c\/p\u003e","brand":"PurePeptide","offers":[{"title":"5mg","offer_id":53386107617623,"sku":null,"price":49.0,"currency_code":"EUR","in_stock":true},{"title":"10mg","offer_id":53386107650391,"sku":null,"price":89.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/Semaglutide_5mg_55bfa366-6dfc-42f3-b518-7a25e8ceb136.png?v=1779544791"},{"product_id":"mots-c","title":"MOTS-c 10mg","description":"\u003ch1 class=\"p1\"\u003eWhat is MOTS-c?\u003c\/h1\u003e\n\u003cp\u003eMOTS-c is a peptide molecule identified by Dr. Ping Ling and a research team from the University of Southern California. It originates from mitochondria—the cellular structures centrally involved in energy production and regulation within the cell.\u003c\/p\u003e\n\n\u003cp\u003eMOTS-c is a relatively new subject of scientific interest and continues to be actively studied to clarify its biological functions more precisely. In published literature, the peptide is considered a mitochondrially-encoded signaling molecule associated with metabolic regulation, energy balance, mitochondrial activity, and cellular adaptation to various stressors.\u003c\/p\u003e\n\n\u003cp\u003eOne of the most frequently discussed aspects of MOTS-c is its role in metabolic control. In experimental models, observations of improved glucose tolerance, increased insulin sensitivity, and influence on cellular mechanisms involved in energy metabolism and metabolic homeostasis have been reported.\u003c\/p\u003e\n\n\u003ch2 class=\"p1\"\u003eObservations with MOTS-c\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic processes\u003c\/strong\u003e – considered in relation to the regulation of glucose metabolism, cellular energy, and the maintenance of metabolic balance.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eInsulin sensitivity\u003c\/strong\u003e – effects related to better glucose control and improved insulin sensitivity have been described in scientific models.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003ePhysical endurance\u003c\/strong\u003e – publications discuss a potential influence on muscle function, physical activity, and adaptation to exercise.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eMitochondrial activity\u003c\/strong\u003e – MOTS-c participates in cellular signaling processes related to maintaining mitochondrial function.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eCellular stress and inflammation\u003c\/strong\u003e – studied in the context of adaptation to metabolic stress and the modulation of chronic inflammatory processes.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003cstrong\u003eCognitive function and sleep\u003c\/strong\u003e – in limited observations, a possible link with cognitive indicators, neurometabolic regulation, and sleep quality is considered.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eScientific Data\u003c\/h2\u003e\n\u003cp\u003eIn publications related to \u003cem\u003eCell Metabolism\u003c\/em\u003e, MOTS-c has been described as a mitochondrial peptide that can activate key metabolic pathways and participate in the regulation of glucose homeostasis. In experimental models, improvements in metabolic control, physical endurance, and cellular response to energy stress have been observed.\u003c\/p\u003e\n\n\u003cp\u003eFurther research considers MOTS-c as a signaling molecule that can communicate with various cells and tissues. In this context, the peptide is being studied in relation to mitochondrial activity, inflammatory processes, cellular adaptation, and mechanisms associated with aging.\u003c\/p\u003e\n\n\u003ch2\u003ePotential effects discussed in scientific literature\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eImprovement of glucose tolerance\u003c\/li\u003e\n\u003cli\u003eImprovement of insulin sensitivity\u003c\/li\u003e\n\u003cli\u003eSupport of mitochondrial function\u003c\/li\u003e\n\u003cli\u003eIncrease in physical endurance\u003c\/li\u003e\n\u003cli\u003eInfluence on metabolic processes\u003c\/li\u003e\n\u003cli\u003eLimitation of chronic inflammatory processes\u003c\/li\u003e\n\u003cli\u003eImproved adaptation to cellular and metabolic stress\u003c\/li\u003e\n\u003cli\u003ePotential link with cognitive function and sleep quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eAdministration and Dosage\u003c\/h2\u003e\n\u003cp\u003eIn some scientific sources, MOTS-c is described with exemplary experimental protocols of around 2.5 mg once every 5 days. These data are presented for informational purposes only and do not constitute a recommendation for use.\u003c\/p\u003e\n\n\u003cp\u003eExample concentrations for 10 mg \/ 2 ml solution:\u003c\/p\u003e\n\u003cp\u003e0.3 ml = 1.5 mg\u003c\/p\u003e\n\u003cp\u003e0.4 ml = 2 mg\u003c\/p\u003e\n\u003cp\u003e0.5 ml = 2.5 mg\u003c\/p\u003e\n\u003cp\u003e0.6 ml = 3 mg\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\n\u003ch2\u003ePossible side effects\u003c\/h2\u003e\n\u003cp\u003eCurrently, there is insufficient large-scale clinical data to allow a full assessment of the safety profile in humans. In limited observations, mild and transient adverse reactions such as:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eheadache\u003c\/li\u003e\n\u003cli\u003enausea\u003c\/li\u003e\n\u003cli\u003estomach discomfort\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDue to the limited volume of human data, no definitive conclusions can be drawn regarding long-term safety, optimal quantities, or effectiveness in various conditions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThe information is summarized based on available scientific publications and is for educational purposes only. It should not be used for diagnosis, treatment, or prevention of diseases.\u003c\/em\u003e\u003c\/p\u003e","brand":"PurePeptide","offers":[{"title":"10mg","offer_id":53408080855383,"sku":null,"price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/files\/MOTS-c_4aea18a0-0bd0-4fb9-b3d4-a92d85a6d26b.png?v=1779544795"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/8902\/6135\/collections\/metabolizm-2324758_82413761-dee9-4190-bed7-91a8b9621c38.jpg?v=1779544790","url":"https:\/\/purepeptide.eu\/collections\/weight.oembed","provider":"PurePeptide","version":"1.0","type":"link"}